Granted Patent B2

US 12,551,495 · App. 17/915,865 · Granted Feb 17, 2026

Inventors: Pierre Dilda (Paris, FR); René Lafont (Paris, FR); Stanislas Veillet (Savigny sur Orge, FR); Samuel Agus (Cambridge, MA); Waly Dioh (Bretigny sur Orge, FR); Serge Camelo (La Plaine Saint-Denis, FR); Mathilde Latil (Paris, FR); Mounia Chabane De Saint Aubin (Paris, FR); Cendrine Tourette (Paris, FR)

Assignees: BIOPHYTIS; SORBONNE UNIVERSITE

A61K31/575A61P11/00A61P31/14

Abstract

Claims (15)

1 . A method for the treatment of an impairment of the respiratory function resulting from a viral infection, by a coronavirus using ACE2 as receptor on the surface of the mammal cells, in mammals, comprising administering to a patient in need thereof, a composition comprising at least 20-hydroxyecdysone.

2 . The method according to claim 1 , wherein the impairment of the respiratory function results from an infection by a SARS-CoV coronavirus.

3 . The method according to claim 1 , wherein the impairment of the respiratory function results from an infection by a SARS-CoV-2 coronavirus.

4 . The method according to claim 1 , wherein the treatment of the impairment of the respiratory function comprises the prevention and treatment of respiratory insufficiency in the mammal suffering from the viral infection.

5 . The method according to claim 1 , wherein the treatment of the impairment of the respiratory function comprises the prevention and treatment of the acute respiratory distress syndrome in the mammal suffering from the viral infection.

6 . The method according to claim 1 , wherein the treatment of the impairment of the respiratory function comprises the treatment of the respiratory muscle function.

7 . The method according to claim 1 , wherein the treatment of the impairment of the respiratory function comprises the treatment of one of the affections of the respiratory function in the mammal suffering from the viral infection selected from hypoxia and reduction in the ability to eliminate CO 2 .

8 . The method according to claim 1 , wherein the impairment of the respiratory function is related to the change in at least one of the parameters selected from:

mortality and curing characterized by transferring the patient to the patient's home or to a general medicine care service,

the number of events of the respiratory insufficiency type, defined by the need for mechanical ventilation and by the need for non-invasive respiratory support,

the sequential respiratory failure evaluation score (SOFA) and the pulmonary severity index (PSI) and medical imaging that makes it possible to graduate the level of progress of the exudative inflammatory pathology,

the plasma level of pro-inflammatory and anti-inflammatory cytokines.

9 . The method according to claim 1 , wherein the 20-hydroxyecdysone is in the form of an extract of a plant or of a part of a plant, said plant being selected from the plants containing at least 0.5% 20-hydroxyecdysone by dry weight of said plant, said extract including at least 95% of 20-hydroxyecdysone.

10 . The method according to claim 9 , wherein the composition includes between 0 and 0.05%, by dry weight of the extract, impurities liable to affect the innocuousness, the availability or the efficacy of a pharmaceutical application of said extract.

11 . The method according to claim 9 , wherein the plant is selected from Stemmacantha carthamoides, Cyanotis arachnoidea and Cyanotis vaga.

Assignments (2)

Priority Claims (1)

Continuity (1)

References Cited (20)